Regencell Bioscience Holdings Ltd

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The lead plaintiff deadline for LKQ is June 22, 2026, for a class period spanning February 27, 2023 to July 23, 2025, with allegations that FinishMaster was losing major customers and that risks from the Uni-Select acquisition had already materialized. Regencell investors have until June 23, 2026, for claims covering October 28, 2024 to October 31, 2025, alleging the company was vulnerable to market manipulation and exposed investors to significant financial risk. Globant's deadline is also June 23, 2026, for a class period from February 15, 2024 to August 14, 2025, with allegations of decreasing demand across Latin America and project cancellations by Latin American clients.

Rosen Law Firm reminds purchasers of Regencell Bioscience Holdings Limited securities between October 28, 2024 and October 31, 2025 of the June 23, 2026 lead plaintiff deadline in a securities class action. If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that throughout the Class Period, defendants made false or misleading statements and failed to disclose that Regencell was vulnerable to market manipulation, exposing investors to significant financial risk and heightened regulatory scrutiny. Investors with losses in excess of $100,000 are encouraged to secure counsel before the deadline.

Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Regencell Bioscience Holdings and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The complaint claims the company made false and misleading statements and failed to disclose vulnerability to market manipulation, exposing investors to significant financial risk and heightened regulatory scrutiny. Investors have until June 23, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.

The Gross Law Firm has issued a reminder to shareholders of Regencell Bioscience Holdings Limited about the upcoming June 23, 2026 deadline to seek lead plaintiff appointment in a securities class action. The class period runs from October 28, 2024 to October 31, 2025, and the complaint alleges that the company made materially false and misleading statements and failed to disclose vulnerability to market manipulation, exposing investors to significant financial risk and heightened regulatory scrutiny. Shareholders who purchased RGC shares during that period are encouraged to register, though participation as a lead plaintiff is not required for any potential recovery. The firm states there is no cost or obligation to participate.

Glancy Prongay Wolke & Rotter LLP reminds investors that June 23, 2026 is the deadline to file a lead plaintiff motion in a class action lawsuit against Regencell Bioscience Holdings Limited. The suit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The complaint alleges the company made false or misleading statements and failed to disclose risks including vulnerability to market manipulation and heightened regulatory scrutiny. On October 31, 2025, Regencell disclosed a Department of Justice investigation into trading in its ordinary shares, causing its stock price to fall $3.09, or 18.56%, to close at $13.56 per share on November 3, 2025.